Research map: A nomogram based on LASSO-logistic regression for predicting tocilizumab-associated hypofibrinogenemia in patients with rheumatic diseases

Back to the article

Papers in this map

  1. MissForest—non-parametric missing value imputation for mixed-type data · Daniel Johannes Stekhoven · 2011 · 6405 citations · Cited by this paper
  2. Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report · 2026 · Related
  3. Polymyositis and Dermatomyositis · Anthony Bohan · 1975 · 5134 citations · Cited by this paper
  4. Linalool in cancer pharmacology: pharmacokinetic limitations and preclinical cytotoxic evidence for translational development · 2026 · Related
  5. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative · Daniel Aletaha · 2010 · 5010 citations · Cited by this paper
  6. Traditional Chinese medicine interventions targeting Wnt/β-catenin signaling in cerebral ischemia/reperfusion injury: a review · 2026 · Related
  7. The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis · William P. Arend · 1990 · 2283 citations · Cited by this paper
  8. NSFC-funded Chinese materia medica research (2015–2024): achievements output, research characteristics, and evolution · 2026 · Related
  9. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. · Jack Gauldie · 1987 · 1656 citations · Cited by this paper
  10. Endothelial EPAS1 as a prognostic and therapeutic target in acute myocardial infarction: integrative bioinformatics, Mendelian randomization and experimental validation · 2026 · Related
  11. Inflammation and coagulation · Marcel M Levi · 2010 · 986 citations · Cited by this paper
  12. Hematopoietic and T-lymphopoiesis-stimulating effects of a fluorinated pyrazolopiperidine β-cyclodextrin complex in cyclophosphamide-induced hematopoietic suppression · 2026 · Related
  13. The regulation of IgA class switching · Andrea Cerutti · 2008 · 762 citations · Cited by this paper
  14. Ganhai Weikang Capsules ameliorate functional dyspepsia in rats by modulating gut microbiota and host metabolic homeostasis · 2026 · Related
  15. Interleukin (IL-6) Immunotherapy · Toshio Tanaka · 2017 · 424 citations · Cited by this paper
  16. Therapeutic potential of traditional Chinese medicine for hyperuricemia: mechanistic insights and clinical prospects · 2026 · Related
  17. Methods for Causality Assessment of Adverse Drug Reactions · Taofikat B. Agbabiaka · 2008 · 367 citations · Cited by this paper
  18. Exercise-induced myokine irisin protects against obesity-associated ischemic stroke via integrin αVβ5 signaling · 2026 · Related
  19. Tocilizumab (Actemra) · Martin Sheppard · 2017 · 335 citations · Cited by this paper
  20. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6 · Alice Wood · 2000 · 239 citations · Cited by this paper
  21. How I use fibrinogen replacement therapy in acquired bleeding · Jerrold H. Levy · 2014 · 170 citations · Cited by this paper
  22. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry · Jurgen Sota · 2022 · 38 citations · Cited by this paper
  23. Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis · Masatake Matsuoka · 2012 · 32 citations · Cited by this paper
  24. Tocilizumab Induced Acquired Factor XIII Deficiency in Patients with Rheumatoid Arthritis · Sho Mokuda · 2013 · 29 citations · Cited by this paper
  25. Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab) · Masayoshi Souri · 2016 · 29 citations · Cited by this paper
  26. Tocilizumab-induced hypofibrinogenemia: A report of 7 cases · Nihal Martis · 2016 · 29 citations · Cited by this paper
  27. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis · Hermine I. Brunner · 2024 · 28 citations · Cited by this paper
  28. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study · Tadashi Okano · 2015 · 27 citations · Cited by this paper
  29. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial · Xiaomei Leng · 2023 · 24 citations · Cited by this paper
  30. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis · Tingyan He · 2023 · 23 citations · Cited by this paper
  31. Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty · Hitoshi Imamura · 2018 · 22 citations · Cited by this paper
  32. Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review · Döndü Üsküdar Cansu · 2019 · 20 citations · Cited by this paper
  33. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies · Markus Perl · 2024 · 17 citations · Cited by this paper
  34. Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia · Qi An · 2024 · 14 citations · Cited by this paper
  35. Sustained tocilizumab-induced hypofibrinogenemia and thrombocytopenia. Comment on: “Tocilizumab-induced hypofibrinogenemia: A report of 7 cases” by Martis et al., Joint Bone Spine 2016, doi: 10.1016/j.jbspin.2016.04.008 · Gianfranco Vitiello · 2017 · 13 citations · Cited by this paper
  36. Estimated Glucose Disposal Rate Associated With Risk of Frailty and Likelihood of Reversion · Dingchun Hou · 2025 · 12 citations · Cited by this paper
  37. Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS) · Beatriz Marinho Silva Romão · 2024 · 9 citations · Cited by this paper
  38. Characteristics, risk factors and a risk prediction model of tocilizumab-induced hypofibrinogenemia: a retrospective real-world study of inpatients · Le Cai · 2025 · 9 citations · Cited by this paper
  39. Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial · Xuehong Chu · 2026 · 8 citations · Cited by this paper

Source: OpenAlex (CC0)